TRT vs testosterone optimization therapy: what the evidence says

What did @chasvitalityrx actually say?

The creator argued that TRT is essentially a trap, comparing it to "amputating your legs instead of just getting a better pair of shoes." The pitch: skip the injections, avoid what they called "biological bankruptcy," and instead use compounds like enclomiphene (misspelled as "nclomaphine" in the video), DHEA, 7-keto DHEA, and progesterone to support the body's natural hormone production. Their central claim is that TRT shuts down your natural testosterone production and fertility permanently, while their "VitaleRex approach" preserves both. They also warned that TRT risks your "blood turning into maple syrup," a reference to polycythemia, or blood thickening from excess red blood cell production.

The framing is aggressive and intentionally commercial. This isn't a neutral education video. It ends with a product pitch dressed as a health philosophy. That matters when evaluating what's being said and what's being sold.

Does the science back this up?

Partially, yes. The core pharmacology here is real. TRT does suppress the hypothalamic-pituitary-gonadal (HPG) axis. LH and FSH drop, often to near zero, and testicular function decreases, including sperm production. That part is well-documented and not controversial.

Enclomiphene, a selective estrogen receptor modulator (SERM), works differently. By blocking estrogen receptors in the hypothalamus, it stimulates the body to produce more LH and FSH, which then drives endogenous testosterone production. A 2013 randomized controlled trial by Kim et al. in BJU International found that enclomiphene maintained testosterone levels and preserved sperm counts in men with secondary hypogonadism, while TRT suppressed spermatogenesis. A 2014 follow-up in the same journal confirmed these effects over 12 months. So the fertility-preservation argument for enclomiphene specifically has real clinical grounding.

The polycythemia warning is also legitimate. A 2017 meta-analysis by Sharma et al. in European Urology confirmed elevated hematocrit as a known TRT side effect requiring monitoring. This isn't a fringe concern.

What did they get wrong (or right)?

Let's give credit where it's due: the HPG axis suppression from TRT, the fertility implications, and the polycythemia risk are all real and worth knowing. Enclomiphene's mechanism is accurately described in broad strokes.

But several claims fall apart under scrutiny. First, TRT is not a "permanent" biological sentence for everyone. Fertility can recover after TRT cessation, though recovery timelines vary significantly. A 2020 review by Wenker et al. in Sexual Medicine Reviews found that most men recover spermatogenesis within 12 months of stopping TRT, though some take longer. Saying men become "sterile for life" is an overstatement that overstates the risk.

Second, the claim that DHEA, 7-keto DHEA, and progesterone "support upstream and downstream hormone pathways" is vague to the point of being meaningless. The evidence for DHEA supplementation improving testosterone in men with normal adrenal function is weak. A 2006 Cochrane-adjacent review by Nair et al. in the New England Journal of Medicine found minimal androgenic effects in men. 7-keto DHEA doesn't convert to testosterone at all. Lumping these with enclomiphene implies they're equivalent contributors, and they're not.

Third, framing TRT as universally inferior ignores that enclomiphene only works in secondary hypogonadism, where the HPG axis is intact. Men with primary hypogonadism, where the testes themselves are the problem, will not respond to this approach. The video doesn't mention this distinction once.

What should you actually know?

Your situation matters more than any creator's preferred protocol. Enclomiphene is a legitimate, FDA-cleared option for certain men with secondary hypogonadism, especially younger men who want to preserve fertility. If that's your situation, it deserves a real conversation with a physician who runs a proper diagnostic workup, including total testosterone, free testosterone, LH, FSH, and a semen analysis if fertility matters to you.

TRT, meanwhile, isn't the villain it's made out to be here. For men with primary hypogonadism, pituitary damage, or cases where the HPG axis simply isn't going to respond to stimulation, TRT remains the standard of care. The risks are real but manageable with proper monitoring, including hematocrit checks and dose adjustments.

What should concern you about this video is what it leaves out. No mention of who's a candidate for enclomiphene versus TRT. No acknowledgment that "nutrient deficiency" approaches have weak evidence as testosterone treatments in men who aren't actually deficient. And the proprietary product pitch at the end should make any skeptical viewer pause before treating this as medical advice.

Get bloodwork. See a clinician who doesn't have a product to sell you. The "third option" framing isn't wrong on its face, but the version presented here is incomplete enough to be misleading for a significant portion of the men watching it.